Back to ListGenetic Checkpoints After Down Syndrome Diagnosis: What Clinicians Should Not Miss
Karyotype testing remains the gold-standard first-line diagnostic tool for confirming Down syndrome (DS). It reliably identifies Trisomy 21 and detects Robertsonian translocations, and in the majority of patients presenting with a typical phenotype, karyotyping alone is sufficient.
That said, karyotyping has well-recognized structural limitations. Low-level mosaicism may go undetected with standard G-banding. Submicroscopic copy number variants and point mutations fall entirely outside its scope. A normal karyotype result, therefore, does not rule out the presence of additional genetic contributors.
The goal of this post is not to advocate for advanced genetic testing in every DS patient. Rather, it is to help clinicians identify the specific clinical scenarios where stopping at karyotype is not enough.
1. The Role and Limits of Karyotyping
Karyotype testing excels at what it was designed to do: confirming the presence of an extra chromosome 21, identifying Robertsonian translocations, and detecting large-scale chromosomal abnormalities. In terms of cost-effectiveness and clinical accessibility, it remains unmatched as a first-tier test.
However, its structural limitations are equally well-established. In other words, a karyotype result of “no abnormality detected” beyond the confirmed trisomy does not mean there are no additional genetic contributors to a patient’s clinical picture.
The clinical decision rule follows from this: in patients with a typical DS presentation, karyotype testing is sufficient. When clinical features are atypical or when unexplained findings are present beyond what DS alone would account for, further testing should be considered.
2. Three Clinical Red Flags Warranting Additional Testing
The following three clinical scenarios each constitute independent indications for additional genetic workup. In these situations, stopping at the karyotype result is not consistent with current evidence-based practice.
2-1. Atypical Phenotype
When a patient presents with developmental delay in the absence of classic DS features, or when congenital anomalies do not match the pattern typically seen in DS, further genetic evaluation is warranted. In these cases, chromosomal microarray (CMA) or sequencing-based testing should be considered. An atypical phenotype is itself a clinical signal that an additional genetic etiology beyond trisomy may be present.
2-2. Suspected Mosaicism
Low-level mosaicism can be missed by standard karyotyping. Clinical suspicion should be raised when a patient’s symptoms are mild or inconsistent, or when functional capacity appears significantly higher than typical for DS. If mosaicism is suspected on clinical grounds, more sensitive testing methods such as FISH or CMA should be pursued. It should be noted that the precise sensitivity thresholds for detecting low-level mosaicism vary depending on the method used and laboratory standards.
2-3. Robertsonian Translocation
Although Robertsonian translocations account for approximately 3–4% of DS cases, their clinical significance is disproportionately high. Closing a consultation without confirming translocation subtype and parental carrier status means recurrence risk counseling cannot be completed accurately. Recurrence risk ranges from approximately 1% in de novo cases to up to 100% in cases where the mother is a carrier of the translocation. Parental karyotyping and sibling screening must be discussed in all confirmed or suspected translocation cases.
3. Diagnostic Anchoring
Following a DS diagnosis, clinicians may develop a tendency to attribute subsequent symptoms and findings to DS itself. When this bias goes unchecked, co-occurring rare genetic conditions may remain undiagnosed.
Cases of DS presenting alongside rare genetic disorders such as CHARGE syndrome and Hirschsprung disease have been documented in the literature. However, it is important to note that large-scale epidemiological data on the true prevalence of such dual diagnoses in DS remain limited. This should be framed as a clinical consideration to remain alert to, rather than an established prevalence figure.
When symptoms persist that cannot be fully explained by DS alone, when prior workup has failed to identify a cause, or when a patient presents with multiple or complex developmental anomalies, WES/WGS and additional genetic testing should be considered. This is the moment where diagnostic gaps can be addressed.
4. When Genetic Testing Is Needed in Parental Counseling
Genetic testing in DS is not solely a matter of characterizing the index patient. Parental counseling conducted before translocation subtype and carrier status are confirmed is, by definition, incomplete. Recurrence risk varies dramatically depending on the mechanism of DS in a given family. De novo Trisomy 21 carries a recurrence risk of approximately 1%, while maternal Robertsonian translocation carriership may result in recurrence risk approaching 100%. Providing accurate family planning guidance requires this information.
When a parental carrier is identified, sibling screening becomes a relevant discussion. Genetic information has implications across the family unit and across future pregnancies. The questions parents most frequently raise — “Could this happen again with our next child?” or “Should our other children be tested?” — can only be answered accurately when the genetic workup is complete.
Is your Down syndrome patient showing features that karyotyping alone cannot explain?
3billion can help you determine whether WES/WGS is the right next step.
References
Get exclusive rare disease updates
from 3billion.
3billion Inc.
3billion is dedicated to creating a world where patients with rare diseases are not neglected in diagnosis and treatment.
